article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Training and development. Staff development and training programmes were largely on pause during the pandemic. However, demand for training has risen significantly since the start of this year as restrictions ease around the world. Harness technology. Embrace mobile learning.

article thumbnail

FDA warning letters highlight CAPA concerns

European Pharmaceutical Review

Amidst numerous warning letters distributed by the US Food and Drug Administration (FDA) to pharmaceutical manufacturers in recent months, in July this year, the US regulatory body published its analysis on drug product quality in 2022. In subsequent years, up to 2022, half this number or less were issued. Edge Biologicals Inc.,

FDA 85
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The cluster effect: Connectivity and collaboration in life sciences hubs

Pharmaceutical Technology

Take Charleston, South Carolina, for example, where a growing number of medical device and pharmaceutical manufacturers, research laboratories and service companies have sprung up or settled in recent years. dollar grant towards the Foundation’s Lowcountry Healthcare Careers Collaborative.

Medical 52
article thumbnail

How can the pharma industry navigate issues in the global supply chain to minimise drug shortages?

pharmaphorum

The pandemic effectively shut down supply chain paths overnight, and as a result, pharmaceutical manufacturers have faced delays and bottlenecks, which have caused drug shortages in healthcare systems.

Pharma 97
article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

Linked to talent, the presence of good universities is another great sign for life sciences, especially institutions with a focus on healthcare. Real estate options, schools, recreational and cultural amenities, healthcare systems, cost of living, transportation, crime and climate are all key considerations.

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

The Guidance will act as a non-binding and evolving resource for companies and provide additional clarification about communications with healthcare professionals (HCPs), healthcare organisations (HCOs), patient organisations (POs), and other stakeholders, including the general public.

Media 88